Thus, the Ukrainian pharmaceutical company can produce and supply the above-mentioned drugs to 95 low- and middle-income countries of the world, in particular to Ukraine.
Oral treatment developed by Pfizer is intended primarily for the treatment of patients with COVID-19 of mild to moderate severity who have a high risk of complications. It is used to prevent deterioration and progression of the disease from mild to moderate severity and to avoid hospitalization.
We would like to remind you that since February 17, 2022, according to the results of the conducted expert examination, the drug for outpatient treatment of COVID-19 – “Paxlovid” from Pfizer – has been approved for use in Ukraine.
The Medicines Patent Pool (MPP) is a United Nations-supported health organization that works to increase access to and promote the development of life-saving medicines for low- and middle-income countries.
